The efficacy of bimatoprost 0.03% monotherapy in patients previously using topical beta-blocker monotherapy for the treatment of glaucoma or ocular hypertension.

Abstract

In an open-label 12-week study, the safety and efficacy of bimatoprost 0.03% was evaluated in 55 patients with open-angle glaucoma or ocular hypertension inadequately controlled by topical beta-blocker monotherapy. Patients discontinued their topical beta-blocker therapy at the baseline visit and began bimatoprost monotherapy that evening. Study visits were at 6 and 12 weeks postbaseline. Bimatoprost reduced intraocular pressure (IOP) 4.5 mm Hg (21.5%; P < .001) from baseline at week 6 and 4.2 mm Hg (19.6%; P < .001) at week 12. Patients were more likely to achieve low target pressures with bimatoprost than with topical beta-blockers. Conjunctival hyperemia was the most commonly reported adverse event. The findings from this study indicate bimatoprost monotherapy provides a substantially greater IOP reduction than topical beta-blocker therapy and allows more patients to achieve a low target pressure. Bimatoprost is an effective alternative to topical beta-blockers for the treatment of glaucoma and ocular hypertension.

• Authors: Richard Quinones, Melissa L Earl
• Journal: Advances in therapy (Adv Ther) 2004 Nov-Dec Vol. 21 Issue 6 Pg. 370-9 ISSN: 0741-238X [Print] United States
• PMID: 15856860 (Publication Type: Clinical Trial, Comparative Study, Journal Article)

Chemical References

• Adrenergic beta-Antagonists
• Amides
• Antihypertensive Agents
• Lipids
• Ophthalmic Solutions
• Cloprostenol
• Bimatoprost

Topics

• Adrenergic beta-Antagonists (pharmacology)
• Aged
• Amides
• Antihypertensive Agents (adverse effects, pharmacology, therapeutic use)
• Bimatoprost
• Cloprostenol (analogs & derivatives)
• Female
• Glaucoma, Open-Angle (drug therapy)
• Humans
• Intraocular Pressure (drug effects)
• Lipids (adverse effects, pharmacology, therapeutic use)
• Male
• Ocular Hypertension (drug therapy)
• Ophthalmic Solutions